Several other brokerages have also issued reports on SVRA. Canaccord Genuity restated a buy rating and issued a $18.00 target price on shares of Mast Therapeutics in a report on Monday, July 17th. Zacks Investment Research upgraded Mast Therapeutics from a hold rating to a buy rating and set a $6.75 target price on the stock in a report on Friday, September 8th. Jefferies Group LLC assumed coverage on Mast Therapeutics in a research report on Friday, September 22nd. They set a buy rating and a $20.00 price target for the company. Finally, JMP Securities assumed coverage on Mast Therapeutics in a research report on Monday, September 11th. They set an outperform rating and a $20.00 price target for the company. Five investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and a consensus target price of $21.30.
Shares of Mast Therapeutics (SVRA) traded up $0.48 during mid-day trading on Tuesday, hitting $9.53. The stock had a trading volume of 125,400 shares, compared to its average volume of 108,529. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. Mast Therapeutics has a 12 month low of $4.60 and a 12 month high of $16.10.
TRADEMARK VIOLATION NOTICE: “Roth Capital Trims Mast Therapeutics, Inc. (NASDAQ:SVRA) Target Price to $32.00” was posted by BBNS and is the property of of BBNS. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/mast-therapeutics-inc-svra-price-target-lowered-to-32-00-at-roth-capital/1746859.html.
In other Mast Therapeutics news, Director Yuri Pikover acquired 50,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was bought at an average price of $7.85 per share, with a total value of $392,500.00. Following the completion of the purchase, the director now owns 150,000 shares of the company’s stock, valued at $1,177,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.93% of the stock is currently owned by insiders.
About Mast Therapeutics
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with our FREE daily email newsletter.